Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (December 2013)
31 slides from Niagen Bioscience's investor presentation, Dec 4, 2013
Slide 1: Investor Presentation December 2013
C ) ChromaDex December 2013 Investor Presentation
Slide 2: Disclaimers
Disclaimers 2 Safe Harbor ‘This presentationand otherwmtten ororal statements made from timeto time by representatives of ChromaDex contain “forwart!Jooking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21£ of the SecuritiesExchange Act of 1934,
Slide 3: ChromaDex Overview/Mission
ChromaDexe Overview/Mission | 3 - ChromaDex is currently commercializing four patented and proprietary ingredient technologies which in aggregate address multi-billion-dollar markets { NIAGEN,._ Nicotinamide riboside PURENEFPGY pTeroPure & caffeine cocrystal eA pler®PUre Pierstibene ProC3G Natural b
Slide 4: Ingredient Technologies Have Commercialization Opportunities in Multi-billion-dollar Markets
ChromaDex? Ingredient Technologies have Commercialization, 4 is® Opportunities in Multi-billion-dollar Markets 4 Commercialization Opportunity Ingredient — Ingredient Technology Size($) CAGR Sales Licensing Dietary Supplements: 30B 7% @ @ Functional Food & Beverage 8% > 7 @ Animal Healtl Cosmetic —S
Slide 5: NIAGEN is the 1st and Only Commercially Available Nicotinamide Riboside
< NIAGEN™ is the 1st and Only Commercially Available Nicotinamide Riboside NIAGEN. » ChromaDex launched NIAGEN™ in May 2013 » Nicotinamide Riboside (NR) — The “Miracle Molecule” - is a compound naturally found in milk and shown to boost nicotinamide adenine dinucleotide (NAD+) levels. NAD+ is a crit
Slide 6: Commercialization of NIAGEN
Commercialization of NAGEN™ 6 — NIAGEN. « NIAGEN™ may have tremendous appeal to the approximately 150 million Americans who are obese or over weight as well as the 75 million aging baby boomers in the U.S. — both of which are actively seeking new dietary supplement solutions for obesity or healthy a
Slide 7: NIAGEN as a Platform
NIAGEN™ as a Platform ik pve Fj Infant Formulas Dietary Supplements } Sports Nutrition NIAGEN. 7, Medical Foods 6 vrron al im) = t) Pharmaceutical Skincare/Cosmetics (=)
Slide 8: NAD+ Research and Studies
Cornell University Dr. Anthony Sauve Qtr A Scnipes WD Reseanen @ instirvre Dr. Brunhilde Felding NAD+ Research and Studies NIAGEN. L Neuroprotection fi Infant formula THE Weight management UNIVERSITY p OF lowa Dr. Charles Brenner umaversire Breast Cancer ULB Rae Dr. Oberdan Leo Massachusetts * Healt
Slide 9: Caffeinated Energy Products Under Increased Regulatory and Political Scrutiny
Caffeinated Energy Products have been Coming Under Increased Regulatory and Political Scrutiny Regardingthe | 9 Possible Risks of Consuming High Amounts of Caffeine te PURENERGY es = March 2012 —a Chicago City Alderman proposed banning energy drinks with at least 180 milligrams of caffeine. * Octobe
Slide 10: PURENERGY is a Unique Combination of pTeroPure and Caffeine
PURENERGY"™ is a Unique Combination of pTeroPure® Pterostilbene and Caffeine, Which is Poised to Revolutionize] 10 ; the Energy Beverage Market , PURENERGY ee a Overview » By cocrystallizing caffeine with pTeroPure® pterostilbene, caffeine’s energy boostis sustained for at least 6 hours? » PURENERGY
Slide 11: PURENERGY Clinical Results
PURENERGY™ Clinical Results "1 ~~ PURENERGY ee 4 The cross-over, clinical study compared the cocrystallized caffeine in PURENERGY™ with ordinary caffeine. The findings of the study showed: PURENERGY™ delivers almost 30% more caffeine into the blood than ordinary caffeine. The rate of caffeine absorp
Slide 12: Blueberries Contain the Antioxidant Pterostilbene
Blueberries Contain the Powerful Antioxidant Pterostilbene which ChromaDex? has Developed and is Monetizing its ial IP-backed & Clinically-studied Brand, pTeroPure® pleréPure pTeroPure® is ChromaDex-branded pterostilbene * Pterostilbene is a phytoalexin (plant defense system) found naturally in blue
Slide 13: pTeroPure Evaluated in a Phase 2/3 Clinical Study
pTeroPure® was Evaluated in a Phase 2/3 Clinical Study [43 Which Showed Statistically Significant Results for Lowering Blood Pressure pleréPure Clinical trial completed at the University of Mississippi Double-blind, randomized, placebo-controlled, IRB-reviewed 80 patients, 4 arms. Ejight-week durati
Slide 14: pTeroPure Success
pTeroPure® Success pleréPure - Launched pTeroPure® brand in Sept. 2010 - First ChromaDex branded ingredient - 40+ products containing pTeroPure® on the market today nz Activator’ i 14
Slide 15: ProC3G - Anthocyanin
ProC3G™ - Anthocyanin 15 ProC3G. Ganthopurs Cyanidin-3-glucoside _ Overview « Anthocyanins are compounds responsible forthe deep purple color in berries, flowers, black rice and other botanicals « Specific anthocyanins have been studied more extensively and have shown promising health benefits —e.g.
Slide 16: Ingredient Technology Patent Portfolio
cS Ingredient Technology Methods of manufacture D Nicotinamide Riboside | + NAD biosynthesis Methods of production | Methods of production (2) + Axonal degeneration protection Q \ DesroMillene | + Methods of manufacture caffeine cocrystal + Composition of matter | Cholesterol reduction (2) + Oxidati
Slide 17: The Legacy Business is a Revenue-generating Platform
bs @ TheLegacy Business is a Revenue-generating Platform with 14 Years of Expertise in the Natural Products Industry |17 wn chencas suy.boseds | sonertrconsutingservices | chemistry-based services herix consultingservices _f Ci p> « © Largest phytochemical © Analytical testing of © Agloballeader in
Slide 18: Legacy Standards & Analytical Services Business Positioned for Growth
The Legacy Standards & Analytical Services Business is 18 Positioned for Growth t Increased consumer demand — natural products industry expected to reach $243B by 2015! t Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences tT Increased regulatory scr
Slide 19: ChromaDex's Unique Business Model
ChromaDex’s Unique Business Model |19 « Established and growing brand een + Thousands of customers worldwide Analytical Services Market » University research UN ie(Se - Customer order flow + Market trends ESTEE LAUDER Proprietary products i Patent protected | Pfizer Scientifically backed @ HERBALIFE
Slide 20: Unique Model Gives Protected, First-mover Advantages
’ ChromaDex’s Unique Model Gives it Protected, |20 s@ First-mover Advantages in Acquiring Ingredient Technologies a / Over250 University & Research ; Insight to Consumer Markets... Over 1500 Industry Customers, i Institution customers } ‘ ! \® Dartmouth i ec) ae VBTY. | \ #2 Washington i i \ Univers
Slide 21: Discovers, Acquires, & Develops Early-stage Ingredient Technologies
ChromaDex? Discovers, Acquires, & Develops Early-stage Proprietary Ingredient Technologies and Commercializes them in Multi-billion-dollar Markets Discover Discover novel, early-stage Acquire these Develop a differentiated Commercialize in multi-billion- Ingredient Technologies, technologies and off
Slide 22: Following the Model of Other Ingredient Technology Companies
& ChromaDex: is Following the Model of Other Ingredient 22 a Technology Companies (a/@) : : MARTEK 0 Patented vegetarian Acquired by DSM for life enriched: omega-3 ingredient $1.08Bin 2010 = © AN: F Acquired by DSM for te: IONS Ber Cllomeg2:3 $550M in July 2012 twellnet through innovation Krill Oil
Slide 23: Received Strategic Investment from DSM Venturing
ChromaDexe Received Strategic Investment from DSM Venturing in October 2013 | 23 DSM BRIGHT SCIENCE. BRIGHTER LIVING. + $2.5 million common stock investment at $0.85/share - Demonstrates DSM’s confidence in the future of ChromaDex as well as our unique business model of acquiring and commercializing
Slide 24: ChromaDex Highlights
FocusedExpertise 2 Aa ae Ingredient Technology Portfolio NIAGEN PURENERGY pleréPure ProC3G Gyanidin-3-glucoside ChromaDexe Highlights 24 ChromaDex’s legacy standards & analytical services business continues to grow at a steady rate as it has over the last 14 years. Its expertise in the natural produ
Slide 25: Additional Company Information
Additional Company Information APPENDIX 25 ©
Slide 26: ChromaDex At a Glance
ChromaDexe At a Glance 26 a « Founded 1999 by CEO, Frank Jaksch e Headquarters: Irvine, CA e Analytical Laboratory: Boulder, CO — Acquired in April 2003 from NaPro BioTherapeutics » Regulatory Consulting: Rockville, MD Irvine, CA Boulder, CO — Acquired Spherix Consulting in December 2012 e Employees
Slide 27: Founded ChromaDex in 1999
Founded ChromaDex in 1999 Int'l Subsidiaries Manager at Phenomenex Expertise in analytical chemistry, product development Recognized industry expert, most recently appearing ‘on Dateline NBC's Hansen Files regarding quality testing in the natural products industry Board of Directors, Natural Product
Slide 28: Shareholder Summary
Shareholder Summary 28 Shareholder Number of Shares AGESis Ownership! Dr. Phillip Frost 15 252,937) 14.55% Opko Health, Inc. (NYSE:OPK) 1,833,333 1.75% DSM Venturing B.V. 2,941,176 2.81% Frank L. Jaksch Jr. (Founder, CEO, Director) 7,993,320 7.62% Other Directors and Officers 17,731,494 16.91% Total
Slide 29: ChromaDex Model in Action — pTeroPure
ChromaDexe Model in Action — pTeroPure® 29 Case Study Discover 2003: Collaborates 2003-2012: Obtains 2009: Pariners with 2012: Partners with USDA to provide exclusive access to USDA | manufacturer to with Glanbia to reference standards for | research & begins achieve commercial- expand distribution
Slide 30: ChromaDex Ingredient Technology Portfolio
ChromaDex Ingredient Technology Portfolio 30 Monetization Clinical Dietary Food & Animal Skin Branded Ingredient | Compound Supply _Safety Development Supplements Beverage _Health Care Pharma plerPure Y @ Vv¥ AMV OC Pterostilbene Pterostilbene- caffeine cocrystal NIAGEN. Riboside ProC3G Sonn piconte
Slide 31: Contact Information
Contact Information 3 ChromaDex, Inc. 10005 Muirlands Blvd., Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0294 www.chromadex.com Investor Relations Bob Prag, President Scott Wilfong, President The Del Mar Consulting Group, Inc. Alex Partners, LLC Phone: 858.794.9500 Phone: 425.242